Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 8/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | BLVRB | P30043 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.38 |
| ▸ | UCHL5 | Q9Y5K5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854577 | 0.91 | GPR52 (0.52) | GPR52PTGER4POLBTDP1L3MBTL1 | |
| SCHEMBL1850248 | 0.89 | GPR52 (0.54) | GPR52PTGER4POLBTDP1L3MBTL1 | |
| SCHEMBL1849911 | 0.88 | GPR52 (0.58) | GPR52PTGER4POLBTDP1L3MBTL1 | |
| SCHEMBL3211059 | 0.87 | GPR52 (0.57) | GPR52POLBTDP1L3MBTL1NPC1 | |
| SCHEMBL1849196 | 0.86 | GPR52 (0.52) | GPR52SMN1; SMN2 | |
| SCHEMBL1850808 | 0.86 | GPR52 (0.55) | GPR52PTGER4POLBTDP1L3MBTL1 | |
| SCHEMBL3207391 | 0.86 | GPR52 (0.75) | GPR52PTGER4 | |
| SCHEMBL1848441 | 0.85 | GPR52 (0.50) | GPR52PTGER4POLBTDP1L3MBTL1 | |
| SCHEMBL1852565 | 0.84 | GPR52 (0.49) | GPR52PTGER4L3MBTL1NPC1RAB9A | |
| SCHEMBL3221864 | 0.84 | GPR52 (0.75) | GPR52PTGER4POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885PTGER4 888/4885POLB 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.